Search clinical trials for: Influenza vaccine

Total 6654 results

1
2
3
4
5
6
7
8
9
10
...
133
134
›

Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine

Influenza

Hungary
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
Emory University

Recruiting

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older

Influenza | Healthy Volunteers

Australia
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
Sinovac Biotech Co., Ltd

Completed

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Influenza

China
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
China National Biotec Group Company Limited
Peking University; Wuhan Institute of Biological Products Co., Ltd; Guizhou Center... and other collaborators

Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Enterovirus Infections | Influenza

China
Oriol Manuel
University of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaborators

Completed

Reducing the Burden of Influenza After Solid-Organ Transplantation (STOP-FLU)

Influenza | Organ Transplantation

Switzerland, Spain
Novartis Vaccines

Completed

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

Influenza

Switzerland
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons

Influenza

Hungary
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

Influenza

France, Germany
University Hospital Inselspital, Berne
Merck Sharp & Dohme LLC; Boehringer Ingelheim; Abbott; Solvay Pharmaceuticals

Completed

Influenza Vaccination in Immunocompromized Patients

Immunosuppression

Switzerland
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
Marshfield Clinic Research Foundation
Centers for Disease Control and Prevention

Completed

Open-Label Influenza Vaccine Evaluation (OLIVE)

Immune Response

United States
Novartis Vaccines

Completed

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

Influenza

Dominican Republic
Novartis
Novartis Vaccines

Completed

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

Influenza

Argentina
Shiraz University of Medical Sciences

Completed

The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients

Hemodialysis Patients

Iran, Islamic Republic of
Pfizer

Completed

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Influenza, Human

United States, Brazil, South Africa, Philippines, New Zealand, Chile, Argentina
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

Influenza

United States, Germany, Philippines, Czechia, France
University of Alabama at Birmingham

Recruiting

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Influenza

United States
Tel-Aviv Sourasky Medical Center

Unknown

Influenza Vaccination in Fibromyalgia Patients

Fibromyalgia Syndrome

Israel
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

Influenza

Germany, Spain, United States, Korea, Republic of, Romania, Taiwan
Pfizer

Active, not recruiting

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Influenza, Human

United States
Protein Sciences Corporation

Completed

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Influenza

United States
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
FluGen Inc

Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Influenza

China
Clifford Craig Medical Research Trust
Johns Hopkins Bloomberg School of Public Health; Monash University; University... and other collaborators

Unknown

Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly

Heterologous Effects of Vaccines

Australia
Tor Biering-Sørensen
Sanofi; Hospital Clinico Universitario de Santiago

Not yet recruiting

Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes

Influenza
Jiangsu Province Centers for Disease Control and...
Changchun Institute of Biological Products Co., Ltd.

Completed

A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months

Influenza

China
Richard Zimmerman MD
Centers for Disease Control and Prevention

Completed

Immunologic Response to Influenza Vaccination in Children and Adolescents

Immune Response | Influenza, Human

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
Novartis Vaccines

Completed

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Seasonal Influenza | Vaccine

Germany
ID Biomedical Corporation, Quebec

Completed

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Seasonal Influenza

China
Hualan Biological Engineering, Inc.

Completed

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Human Influenza

China
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Completed

Immunogenicity and Safety Study of Self-amplifying MRNA COVID-19 Vaccine Administered with Influenza Vaccines in Adults

COVID-19

Australia, Costa Rica, Honduras, Philippines
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States

1
2
3
4
5
6
7
8
9
10
...
133
134
›

3

Subscribe